

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**February 15, 2024**

---

**I Amendment**

**A022104**, The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer (Version Date 01/12/24)

---

**II Continuing Review**

**A021602**, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) (Version Date 02/03/23)

---

**III Continuing Review**

**A021804**, A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma (Version Date 07/21/23)

---

**IV Continuing Review**

**EAA173**, Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) (Version Date 07/25/23)

---

**V Continuing Review**

**N0577**, N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (Version Date 04/10/23)

---

## **VI Continuing Review**

**NRG-GU002**, Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation following Radical Prostatectomy with or without Adjuvant Docetaxel (Version Date 08/26/19)

---

## **VII Continuing Review**

**NRG-GU012**, Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) (Version Date 01/03/24)

---

## **VIII Continuing Review**

**NRG-GY022**, Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin (Version Date 09/21/22)

---

## **IX Continuing Review**

**S2107**, Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer (Version Date 08/10/23)

---

## **X Continuing Review**

**S2005**, A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL) (Version Date 10/27/23)

---



FOR THE NATIONAL CANCER INSTITUTE

## **XI Continuing Review**

**10272**, A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer (Version Date 04/18/22)

---

## **XII Continuing Review**

**EA2174**, A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma (Version Date 08/15/23)

---